Adapalene and tretinoin: how receptor binding shapes their actions

Abstract

Adapalene and tretinoin are topical retinoids used in acne, but they do not have the same retinoic acid receptor (RAR) profile. Tretinoin (all-trans retinoic acid) activates all three RAR subtypes—RAR alpha, RAR beta and RAR gamma—while adapalene preferentially activates RAR beta and RAR gamma, with weak activity at RAR alpha. [1], [2], [3] These receptors regulate gene transcription and thereby influence epidermal-cell proliferation and differentiation; RARs often signal as DNA-bound pairs with retinoid X receptors (RXRs). [4], [5] The distinction helps explain how both agents can normalise follicular keratinisation while producing different pharmacologic and tolerability profiles. [2], [6]

Introduction

Topical retinoids act inside cells rather than through a cell-surface receptor. Their main molecular targets are nuclear RARs, which regulate the activity of genes involved in cell growth and differentiation. [4] In the skin, these receptors commonly bind DNA as RAR–RXR heterodimers at retinoic-acid response elements. [5] RXR is thus an important signalling partner; its participation does not, by itself, mean that a topical retinoid directly targets RXR. [5]

Schematic of retinoid receptor signalling and downstream skin effects. RAR/RXR gene-regulatory signalling affects keratinocyte biology and acne-relevant processes.

Figure 1. Simplified schematic of RAR–RXR-mediated gene regulation and selected downstream effects in epidermal biology and acne. [5], [6], [7] The lower boxes illustrate related outcomes, not a single linear sequence.

RARs regulate transcription in response to retinoid ligands. In epidermal cells, this signalling influences proliferation and differentiation, processes that contribute to normal epithelial homeostasis. [4], [7] RAR? is particularly relevant to skin because it is the predominant RAR subtype reported in human skin; RAR beta not readily detected in human keratinocytes. [2], [8]

Receptor binding: tretinoin versus adapalene

Tretinoin is all-trans retinoic acid, the active form of vitamin A, and activates RAR alpha, RAR beta and RAR gamma. [1] Its broad RAR activity can therefore engage multiple receptor subtypes, although the resulting response depends on receptor availability and the genes expressed in a particular cell. [4], [5]

Adapalene is a synthetic naphthoic-acid retinoid with preferential activity at RAR beta and RAR gamma. [2], [9] A receptor-binding study characterised it as a mixed RAR beta/gamma agonist, with considerably weaker binding to RAR alpha than to RAR beta or RAR gamma. [3] Because RAR beta is not expressed in human keratinocytes, adapalene’s action in this major epidermal cell type is thought to be mediated chiefly through RAR gamma. [2]

Schematic comparison of the principal RAR activity of tretinoin and adapalene. RXR is shown separately as the heterodimer partner, not as the principal drug target.

Figure 2. Relative receptor activity summarised from the retrieved pharmacology literature. “Preferential” denotes a relative receptor preference, not exclusive binding; receptor expression and cellular context influence the response. [2], [3], [5]

What the receptor difference means in acne

In acne, altered follicular keratinisation contributes to microcomedone formation. Retinoids help normalise this process and have comedolytic effects; topical retinoids also exert anti-inflammatory actions. [2], [6] Adapalene additionally has laboratory evidence of immunomodulatory effects: one study in human skin explants found reduced keratinocyte Toll-like receptor 2 expression after adapalene exposure, a potential contributor to its anti-inflammatory activity. [10]

Receptor selectivity is one plausible contributor to the difference in local tolerability, but it should not be treated as the only explanation or as a guarantee of an individual response. In a 12-week randomised study of people with mild-to-moderate acne, adapalene 0.1% gel and tretinoin 0.025% gel had similar efficacy; adapalene had lower scores for burning, dryness and scaling at specified visits. [11] That comparison applies to the tested formulations and concentrations, not necessarily to every product or patient.

Conclusion

The key pharmacologic contrast is broad activation of RAR alhpa, RAR beta and RAR gamma by tretinoin versus preferential RAR beta/gamma activity by adapalene. [1], [2], [3] RAR–RXR complexes regulate gene transcription, and the resulting changes in epidermal-cell growth and differentiation help explain how both drugs can improve comedonal acne. [4], [5], [6] Their receptor profiles are useful for understanding their mechanisms, but clinical differences also depend on formulation, concentration and patient response. [11]

Evidence note: The source passages available for this article were abstracts and excerpts; detailed mechanistic claims should be interpreted with that limitation.

References

1. B. Shroot, D. Gibson, and X. Lu, “Retinoid receptor-selective agonists and their action in skin,” 1999, doi: 10.1007/978-3-642-58483-1_19 10.1007/978-3-642-58483-1_19.
2. S. Michel, A. Jomard, and M. Démarchez, “Pharmacology of adapalene,” The British journal of dermatology, 1998, doi: 10.1046/j.1365-2133.1998.1390s2003.x. 10.1046/j.1365-2133.1998.1390s2003.x.
3. B. Charpentier et al., “Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes,” Journal of medicinal chemistry, 1995, doi: 10.1021/jm00026a006. 10.1021/jm00026a006.
4. C. Apfel, M. Crettaz, and P. K. LeMotte, “Differential binding and activation of synthetic retinoids to retinoic acid receptors,” Retinoids in Normal Development and Teratogenesis, 1992, doi: 10.1093/oso/9780198547709.003.0005. 10.1093/oso/9780198547709.003.0005.
5. J. H. Xiao, B. Durand, P. Chambon, and J. J. Voorhees, “Endogenous retinoic acid receptor (RAR)-retinoid x receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers to confer ligand-dependent activation of hRAR beta 2/RARE (DR5),” The Journal of biological chemistry, 1995, doi: 10.1074/jbc.270.7.3001. 10.1074/jbc.270.7.3001.
6. J. B. Bikowski, “Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids,” Journal of drugs in dermatology : JDD, 2005, Available: https://pubmed.ncbi.nlm.nih.gov/15696984 https://pubmed.ncbi.nlm.nih.gov/15696984
7. R. L. Beard and R. A. S. Chandraratna, “RAR-selective ligands: Receptor subtype and function selectivity,” Handbook of experimental pharmacology, 1999, doi: 10.1007/978-3-642-58483-1_6. 10.1007/978-3-642-58483-1_6.
8. A. Krust, P. Kastner, M. Petkovich, A. Zelent, and P. Chambon, “A third human retinoic acid receptor, hRAR-gamma,” Proceedings of the National Academy of Sciences of the United States of America, 1989, doi: 10.1073/pnas.86.14.5310. 10.1073/pnas.86.14.5310.
9. R. N. Brogden and K. E. Goa, “Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne,” Drugs, 1997, doi: 10.2165/00003495-199753030-00010. 10.2165/00003495-199753030-00010.
10. I. Tenaud, A. Khammari, and B. Dreno, “In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions,” Experimental dermatology, 2007, doi: 10.1111/j.1600-0625.2007.00552.x. 10.1111/j.1600-0625.2007.00552.x.
11. W. Cunliffe et al., “Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris. A european multicentre trial,” Journal of Dermatological Treatment, 1997, doi: 10.3109/09546639709160514. 10.3109/09546639709160514.